The application of a small-molecular tyrosine kinase inhibitor (TKI), imatinib, has revolutionized the treatment of GISTs, resulting in prolonged recurrence-free survival (RFS) and overall survival (OS) in patients with advanced, inoperable, or high-risk disease.[18] KIT exon 11 mutations in GIST have the highest responses to imatinib at an effective dose of 400 mg/d, whereas KIT exon 9 mutations need 800 mg/d imatinib to achieve a clinical response. Here, KIT is linked to gastrointestinal stromal tumor.